US court upholds Vectura damages award against GSK

13 September 2019

UK-based inhaled therapies developer Vectura (LSE: VEC) today said that, following the award of $89.7 million in damages to Vectura by a jury in the US District Court for the District of Delaware on May 3, 2019, presiding US District Judge Richard Andrews has ruled on the parties’ post-trial motions:

Award of $89.7 million in damages upheld.
Ongoing royalties of 3% on US sales of certain infringing GlaxoSmithKline’s (LSE: GSK) Ellipta inhaled products.
Supplemental damages based on GSK’s infringing sales of about $10.5 million.
Pre-judgment interest at the prime rate of approximately $6.7 million.

“The judge’s post-motions ruling further validates Vectura’s original decision to pursue this action with GSK. We will always take action to protect and defend our intellectual property and we will provide further updates on this matter in due course,” commented Vectura’s chief financial officer and interim chief executive Paul Fry.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK